Not All Types of Atrial Fibrillation Carry the Same Stroke Risk, but Most Benefit From Oral Anticoagulation

Affiliations

¹ From the Division of Clinical Electrophysiology, Department of Cardiology, J. W. Goethe University, Frankfurt, Germany. hohnloser@em.uni-frankfurt.de.
² From the Division of Clinical Electrophysiology, Department of Cardiology, J. W. Goethe University, Frankfurt, Germany.

Editorial

Stefan H Hohnloser et al. Circ Arrhythm Electrophysiol. 2017 Jan.

. 2017 Jan;10(1):e004847.

doi: 10.1161/CIRCEP.116.004847.

¹ From the Division of Clinical Electrophysiology, Department of Cardiology, J. W. Goethe University, Frankfurt, Germany. hohnloser@em.uni-frankfurt.de.
² From the Division of Clinical Electrophysiology, Department of Cardiology, J. W. Goethe University, Frankfurt, Germany.

No abstract available

Keywords: Editorials; anticoagulant; atrial fibrillation; embolism; hypertension; stroke.

Comment on

Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, Crompton AE, Murphy SA, Lanz H, Mercuri MF, Antman EM, Braunwald E; ENGAGE AF-TIMI 48 Investigators. Link MS, et al. Circ Arrhythm Electrophysiol. 2017 Jan;10(1):e004267. doi: 10.1161/CIRCEP.116.004267. Circ Arrhythm Electrophysiol. 2017. PMID: 28077507 Clinical Trial.